Abstract
Introduction. Cases of Chikungunya fever have been reported in more than 100 countries in Europe, Oceania, Africa, Asia, the Caribbean, and America. The musculoskeletal disorders typical for Chikungunya fever can last from several months to a year and even lead to disability. The infection is believed to provide lifelong immunity. This factor and the lack of specific therapy make vaccination the most promising method for preventing Chikungunya fever.Materials and methods. The purified inactivated preparation with the different doses of the CHIKV antigen was injected intramuscularly to BALB/c mice twice with an interval of 14 days. Indicators of humoral and cellular immunity were assessed in dynamics in ELISA, the neutralization test and proliferation test of splenocytes. Results. The purified preparation containing the CHIKV antigen inactivated by beta-propiolactone had pronounced immunogenic properties. The most prominent immune response in ELISA and neutralization test was registered for a dose of 40 μg. Stimulation with the specific CHIKV antigen caused a pronounced proliferation of animals' splenocytes. The peak values of specific humoral and cellular immunity parameters were registered 14 days after the second injection.Discussion. The purified preparation containing the CHIKV antigen inactivated by beta-propiolactone had demonstrated the sufficient immunogenic properties. The immunizing dose of 40 μg CHIKV selected as a result of the studies caused in BALB/c mice the development of the humoral immunity characterized by the specific IgG with neutralizing activity, and the specific cell immunity characterized by the animals' splenocytes proliferation after stimulation with CHIKV antigen.Conclusion. The purified β-PL inactivated preparation of the CHIKV antigen at a dose of 40 μg to demonstrated pronounced immunogenicity in BALB/c mice after two-dose immunization. The developed preparation can be considered as promising for the prevention of Chikungunya fever using the dose and scheme tested in this study.
Highlights
Cases of Chikungunya fever have been reported in more than 100 countries in Europe, Oceania, Africa, Asia, the Caribbean, and America
Indicators of humoral and cellular immunity were assessed in dynamics in ELISA, the neutralization test and proliferation test of splenocytes
The purified preparation containing the CHIKV antigen inactivated by beta-propiolactone had pronounced immunogenic properties
Summary
Содержащего 10 мкг антигена ЧИКВ, вызывала незначительный подъём специфических антител в группе А после 2-й иммунизации с падением к 35-м суткам наблюдения Содержащего 25 мкг антигена ЧИКВ, привело к формированию достаточно высокого уровня специфических антител в группе В на 14-е сутки после 2-й иммунизации, который, однако, также снизился к 35-м суткам наблюдения Для дальнейших исследований клеточного иммунного ответа был выбран препарат с дозой антигена ЧИКВ 40 мкг как обеспечивший наиболее выраженный и стабильный гуморальный иммунный ответ у мышей линии BALB/c после двукратной иммунизации. Титр специфических антител в сыворотке мышей линии BALB/c, иммунизированных препаратом с разным содержанием антигена ЧИКВ в динамике Table 1. Показатели вируснейтрализующих антител в сыворотке мышей линии BALB/c, иммунизированных препаратом с разным содержанием антигена ЧИКВ, в динамике (M ± SD) Table 2. Proliferative activity of splenocytes from BALB/c mice immunized with the preparation contained different CHIKV antigen dose (M ± SD)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
